How Long Will Fulgent Genetics Benefit From the Pandemic?
In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss how long that benefit could last and how investors should value the company accordingly. Brian Orelli: The number of COVID-19 tests performed in the U.S. has been dropping precipitously. Speights: No. That's what Fulgent did in Q1.